JP2001525669A - 細胞遊走の阻害のための方法および構築物 - Google Patents
細胞遊走の阻害のための方法および構築物Info
- Publication number
- JP2001525669A JP2001525669A JP54907798A JP54907798A JP2001525669A JP 2001525669 A JP2001525669 A JP 2001525669A JP 54907798 A JP54907798 A JP 54907798A JP 54907798 A JP54907798 A JP 54907798A JP 2001525669 A JP2001525669 A JP 2001525669A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- domain
- recombinant nucleic
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 32
- 230000012292 cell migration Effects 0.000 title claims abstract description 21
- 230000002401 inhibitory effect Effects 0.000 title claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 72
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 62
- 210000004027 cell Anatomy 0.000 claims abstract description 58
- 239000013598 vector Substances 0.000 claims abstract description 55
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 49
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 49
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 49
- 102000005962 receptors Human genes 0.000 claims abstract description 36
- 108020003175 receptors Proteins 0.000 claims abstract description 36
- 230000000694 effects Effects 0.000 claims abstract description 27
- 229920001184 polypeptide Polymers 0.000 claims abstract description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 24
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract description 21
- 210000001519 tissue Anatomy 0.000 claims abstract description 19
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 19
- 238000010361 transduction Methods 0.000 claims abstract description 16
- 230000026683 transduction Effects 0.000 claims abstract description 16
- 238000001890 transfection Methods 0.000 claims abstract description 16
- 239000012636 effector Substances 0.000 claims abstract description 13
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims abstract description 12
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 11
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 10
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 10
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 10
- 230000007838 tissue remodeling Effects 0.000 claims abstract description 9
- 230000015556 catabolic process Effects 0.000 claims abstract description 8
- 238000006731 degradation reaction Methods 0.000 claims abstract description 8
- 230000002797 proteolythic effect Effects 0.000 claims abstract description 7
- 230000004709 cell invasion Effects 0.000 claims abstract description 6
- 230000002463 transducing effect Effects 0.000 claims abstract description 4
- 230000003612 virological effect Effects 0.000 claims abstract description 4
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 3
- 239000013603 viral vector Substances 0.000 claims abstract description 3
- 238000011084 recovery Methods 0.000 claims abstract 2
- 239000003112 inhibitor Substances 0.000 claims description 22
- 102000035195 Peptidases Human genes 0.000 claims description 19
- 108091005804 Peptidases Proteins 0.000 claims description 19
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 18
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 15
- 229960005356 urokinase Drugs 0.000 claims description 14
- 239000004365 Protease Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 12
- 241000283690 Bos taurus Species 0.000 claims description 11
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 9
- 239000002753 trypsin inhibitor Substances 0.000 claims description 9
- 102000005741 Metalloproteases Human genes 0.000 claims description 7
- 108010006035 Metalloproteases Proteins 0.000 claims description 7
- 229940122618 Trypsin inhibitor Drugs 0.000 claims description 7
- 101710162629 Trypsin inhibitor Proteins 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- 239000013605 shuttle vector Substances 0.000 claims description 6
- 108010088854 urinastatin Proteins 0.000 claims description 6
- 210000002889 endothelial cell Anatomy 0.000 claims description 5
- 210000000952 spleen Anatomy 0.000 claims description 5
- 101710126321 Pancreatic trypsin inhibitor Proteins 0.000 claims description 4
- 108010023795 VLDL receptor Proteins 0.000 claims description 4
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 claims description 4
- 239000003602 elastase inhibitor Substances 0.000 claims description 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 3
- 102000001851 Low Density Lipoprotein Receptor-Related Protein-1 Human genes 0.000 claims description 3
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 claims description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 claims description 3
- 229940116977 epidermal growth factor Drugs 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 3
- 229940122858 Elastase inhibitor Drugs 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 claims 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 43
- 239000012634 fragment Substances 0.000 description 36
- 108020004414 DNA Proteins 0.000 description 24
- 108010039627 Aprotinin Proteins 0.000 description 18
- 108091008146 restriction endonucleases Proteins 0.000 description 14
- 108010088842 Fibrinolysin Proteins 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 12
- 229940012957 plasmin Drugs 0.000 description 12
- 239000013604 expression vector Substances 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 8
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 238000010276 construction Methods 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 5
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000008692 neointimal formation Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 5
- 102000000844 Cell Surface Receptors Human genes 0.000 description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 description 4
- 241001135569 Human adenovirus 5 Species 0.000 description 4
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 210000002437 synoviocyte Anatomy 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 3
- 108010051456 Plasminogen Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000002806 plasmin inhibitor Substances 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 101100257820 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ssp-1 gene Proteins 0.000 description 2
- 229940122791 Plasmin inhibitor Drugs 0.000 description 2
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 2
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 2
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 description 2
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101100153326 Bos taurus TIMP1 gene Proteins 0.000 description 1
- 101000573945 Coccidioides posadasii (strain C735) Neutral protease 2 homolog MEP2 Proteins 0.000 description 1
- 101000573882 Coccidioides posadasii (strain C735) Neutral protease 2 homolog MEP3 Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 101000972918 Homo sapiens MAX gene-associated protein Proteins 0.000 description 1
- 101000760337 Homo sapiens Urokinase plasminogen activator surface receptor Proteins 0.000 description 1
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102100022621 MAX gene-associated protein Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 101150064009 PLLP gene Proteins 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 101710180319 Protease 1 Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101710146873 Receptor-binding protein Proteins 0.000 description 1
- 101150068258 STI gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 102000005406 Tissue Inhibitor of Metalloproteinase-3 Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 101710180677 Urokinase plasminogen activator surface receptor Proteins 0.000 description 1
- 102100024689 Urokinase plasminogen activator surface receptor Human genes 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012897 dilution medium Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000015590 smooth muscle cell migration Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003422 vasoregulatory effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
- C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97201423 | 1997-05-12 | ||
EP97201423.7 | 1997-05-12 | ||
PCT/NL1998/000259 WO1998051788A2 (fr) | 1997-05-12 | 1998-05-11 | Procede et construction pouvant inhiber une migration cellulaire |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001525669A true JP2001525669A (ja) | 2001-12-11 |
Family
ID=8228315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54907798A Ceased JP2001525669A (ja) | 1997-05-12 | 1998-05-11 | 細胞遊走の阻害のための方法および構築物 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0981606A2 (fr) |
JP (1) | JP2001525669A (fr) |
AU (1) | AU7553698A (fr) |
CA (1) | CA2289117A1 (fr) |
NO (1) | NO995564L (fr) |
NZ (1) | NZ500656A (fr) |
WO (1) | WO1998051788A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999055365A1 (fr) | 1998-04-30 | 1999-11-04 | Cornell Research Foundation, Inc. | Vecteurs adenoviraux avec proteines a deux types de genes de fibre |
US6455314B1 (en) | 1998-09-11 | 2002-09-24 | Genvec, Inc. | Alternatively targeted adenovirus |
DE10020125A1 (de) | 2000-04-18 | 2001-10-25 | Friedrich Schiller Uni Jena Bu | Agens für den postoperativen Einsatz nach Entfernung von Knochentumoren |
EP1903113A1 (fr) * | 2000-12-18 | 2008-03-26 | Arriva Pharmaceuticals, Inc. | Inhibiteurs de protéase multifonctionnels et leur utilisation dans le traitement de maladies |
AU2002241661B2 (en) * | 2000-12-18 | 2007-05-31 | Arriva Pharmaceuticals, Inc | Multifunctional protease inhibitors and their use in treatment of disease |
US7247704B2 (en) | 2000-12-18 | 2007-07-24 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
ATE467680T1 (de) | 2001-10-11 | 2010-05-15 | Merck Sharp & Dohme | Hepatitis-c-virus-impfstoff |
DE60236364D1 (en) * | 2001-10-11 | 2010-06-24 | Angeletti P Ist Richerche Bio | Hepatitis-c-virus-impfstoff |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0318554B2 (fr) * | 1987-05-21 | 2005-01-12 | Micromet AG | Proteines mutifonctionnelles a cible predeterminee |
US5504001A (en) * | 1987-11-25 | 1996-04-02 | Zymogenetics, Inc. | Hybrid plasminogen activator |
DE69025211T2 (de) * | 1989-02-17 | 1996-09-19 | Merck & Co Inc | Protein-Antikrebsmittel |
JP2877509B2 (ja) * | 1989-05-19 | 1999-03-31 | アムジエン・インコーポレーテツド | メタロプロテイナーゼ阻害剤 |
ES2060134T3 (es) * | 1989-05-26 | 1994-11-16 | Univ Washington | Inhibidor de tejido de metaloproteasas (timp-2). |
AU657087B2 (en) * | 1989-12-22 | 1995-03-02 | Seragen Incorporated | Hybrid molecules having translocation region and cell-binding region |
ATE212059T1 (de) * | 1990-02-15 | 2002-02-15 | Methoden zur identifizierung heterofunktionaler fusionsproteine | |
GB2246779B (en) * | 1990-08-03 | 1994-08-17 | Delta Biotechnology Ltd | Tumour-associated protease inhibitors targeted to tumour cells |
JPH09504174A (ja) * | 1993-10-29 | 1997-04-28 | インサイト ファーマシューティカルズ,インク. | プロテアーゼネキシン1変異体を含むキメラ蛋白 |
WO1995013091A1 (fr) * | 1993-11-12 | 1995-05-18 | International Technology Management Associates, Ltd. | Procedes pour la reparation de tissu conjonctif |
US5550213A (en) * | 1993-12-27 | 1996-08-27 | Rutgers, The State University Of New Jersey | Inhibitors of urokinase plasminogen activator |
DE69533472T2 (de) * | 1994-01-11 | 2006-01-12 | Dyax Corp., Cambridge | Kallikreinhemmende "kunitz-domäne"-proteine und derivaten davon |
WO1995028955A1 (fr) * | 1994-04-22 | 1995-11-02 | Gliemann Joergen | PEPTIDES SE LIANT A LA PROTEINE ASSOCIEE AU RECEPTEUR DE MACROGLOBULINE-α2/RECEPTEUR DE LIPOPROTEINE DE FAIBLE DENSITE |
US5712149A (en) * | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
US5843724A (en) * | 1995-04-27 | 1998-12-01 | Rutgers University | Chimeric nucleic acids and proteins for inhibiting HIV-1 expression |
US5726050A (en) * | 1995-06-20 | 1998-03-10 | Massachusetts Institute Of Technology | Z-DNA binding protein and applications |
AU1210797A (en) * | 1996-01-08 | 1997-08-01 | Nissin Food Products Co., Ltd. | Cancerous metastasis inhibitor |
-
1998
- 1998-05-11 EP EP98923197A patent/EP0981606A2/fr not_active Withdrawn
- 1998-05-11 CA CA002289117A patent/CA2289117A1/fr not_active Abandoned
- 1998-05-11 NZ NZ500656A patent/NZ500656A/en unknown
- 1998-05-11 JP JP54907798A patent/JP2001525669A/ja not_active Ceased
- 1998-05-11 AU AU75536/98A patent/AU7553698A/en not_active Abandoned
- 1998-05-11 WO PCT/NL1998/000259 patent/WO1998051788A2/fr not_active Application Discontinuation
-
1999
- 1999-11-12 NO NO995564A patent/NO995564L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0981606A2 (fr) | 2000-03-01 |
WO1998051788A3 (fr) | 1999-05-20 |
NZ500656A (en) | 2001-11-30 |
NO995564D0 (no) | 1999-11-12 |
NO995564L (no) | 2000-01-11 |
WO1998051788A2 (fr) | 1998-11-19 |
CA2289117A1 (fr) | 1998-11-19 |
AU7553698A (en) | 1998-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Axelrod et al. | Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells | |
US7807621B2 (en) | Anti-invasive and anti-angiogenic compositions | |
Barnathan et al. | Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA | |
US5801146A (en) | Compound and method for inhibiting angiogenesis | |
JP3787157B2 (ja) | アンジオスタチンフラグメント、アンジオスタチン凝集体および使用方法 | |
US20070117180A1 (en) | Enzyme producing plasma protein fragment having inhibitory activity to metastasis and growth of cancer and plasma protein fragment produced by fragmentation by said enzyme | |
JP2006213724A (ja) | アンジオスタチンおよび血管形成の抑制におけるその使用 | |
Fen et al. | Structural organization and chromosomal assignment of the gene encoding the human heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor | |
JPH10117787A (ja) | ファクターvii活性を有する蛋白質の製造方法 | |
JP2012135307A (ja) | Pai−1機能の治療的阻害因子およびその使用法 | |
Conte et al. | Genetic interventions for vein bypass graft disease: a review | |
JP2001525669A (ja) | 細胞遊走の阻害のための方法および構築物 | |
FI103577B (fi) | Menetelmä, DNA ja mikro-organismi trombolyyttisen aineen valmistamisek si | |
JP2006516113A5 (fr) | ||
RU2143490C1 (ru) | Бифункциональный вариант урокиназы, плазмида, содержащая синтетический структурный ген, кодирующий бифункциональную урокиназу, плазмида (варианты), способ получения плазмиды, способ получения бифункционального варианта урокиназы, тромболитическое средство | |
JP4733337B2 (ja) | ヒトのウロキナーゼ型プラスミノゲン活性化因子の遺伝子を含む組換えウイルスベクターおよび非ウイルスベクター、および肝線維症、腎線維症、肺線維症、膵線維症、心臓線維症などのさまざまなタイプの線維症、および肥厚性瘢痕の治療におけるその有用性 | |
More et al. | Changes in vessel wall plasminogen activator activity and smooth muscle cell proliferation and activation after arterial injury | |
JPH05194264A (ja) | 血栓塞栓障害治療剤 | |
Harvey et al. | Transfer of the α5 (IV) collagen chain gene to smooth muscle restores in vivo expression of the α6 (IV) collagen chain in a canine model of Alport syndrome | |
JPH02436A (ja) | 新規な線維素溶解酵素 | |
JP2004194665A (ja) | 血管内皮細胞増殖因子の変異体 | |
WO2000049871A1 (fr) | Proteine kringle antiangiogenique et ses mutants | |
JP2002535372A (ja) | プラスミノーゲンクリングル4領域フラグメントおよび利用法 | |
Lamfers et al. | Adenoviral gene transfer of a u-PA receptor-binding plasmin inhibitor and green fluorescent protein: inhibition of migration and visualization of expression | |
Dichek | Gene transfer in the treatment of thrombosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050510 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080624 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20081118 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090210 |